Search results for "Random"

showing 10 items of 3931 documents

Fecal microbiota transplantation to maintain remission in Crohn’s disease: a pilot randomized controlled study

2020

Abstract Background The role of the gut microbiota in Crohn’s disease (CD) is established and fecal microbiota transplantation (FMT) is an attractive therapeutic strategy. No randomized controlled clinical trial results are available. We performed a randomized, single-blind, sham-controlled pilot trial of FMT in adults with colonic or ileo-colonic CD. Method Patients enrolled while in flare received oral corticosteroid. Once in clinical remission, patients were randomized to receive either FMT or sham transplantation during a colonoscopy. Corticosteroids were tapered and a second colonoscopy was performed at week 6. The primary endpoint was the implantation of the donor microbiota at week 6…

Microbiology (medical)AdultMaleCrohn’s diseasemedicine.medical_specialtymedicine.drug_class[SDV]Life Sciences [q-bio]ColonoscopyPilot ProjectsGut floraMicrobiologyGastroenterologySeverity of Illness Indexlcsh:Microbial ecologylaw.inventionFecal microbiota transplantation03 medical and health sciencesFeces0302 clinical medicineRandomized controlled trialCrohn DiseaselawAdrenal Cortex HormonesInternal medicinemedicineClinical endpointHumansSingle-Blind Method030304 developmental biology0303 health sciencesCrohn's diseasebiologymedicine.diagnostic_testMicrobiotaResearchRemission Inductionbiology.organism_classificationmedicine.disease3. Good healthClinical trialTransplantationCrohn's diseaseTreatment OutcomeResearch DesignRandomized controlled trialCorticosteroidlcsh:QR100-130030211 gastroenterology & hepatologyFemaleMicrobiome
researchProduct

Fungemia due to Candida guilliermondii in a pediatric and adult population during a 12-year period.

2007

Candida guilliermondii fungemia is usually described in adults with hematologic malignancies, but in children, only 2 episodes have been published. From 1995 to 2006, 7 episodes (5 in children) were detected in our hospital. Molecular typing excluded a common infection source. C. guilliermondii fungemia may occur in children with underlying conditions other than cancer.

Microbiology (medical)AdultMalePediatricsmedicine.medical_specialtyGenotypeAdult populationBiologyMolecular typingmedicineHumansCandida guilliermondiiIntensive care medicineChildMycological Typing TechniquesFungemiaMycosisCandidaMolecular EpidemiologyCandidiasisInfant NewbornInfantGeneral MedicineMiddle Agedbacterial infections and mycosesmedicine.diseaseDNA FingerprintingRandom Amplified Polymorphic DNA TechniqueHospitalizationInfectious DiseasesChild PreschoolFemaleC. guilliermondiiFungemiaDiagnostic microbiology and infectious disease
researchProduct

A double-blind trial on prophylactic voriconazole (VRC) or placebo during induction chemotherapy for acute myelogenous leukaemia (AML).

2007

Summary Objectives Invasive fungal infections remain a frequent cause of morbidity and mortality in long-term neutropenic patients. The availability of tolerable broad-spectrum antifungals like voriconazole stimulated the discussion about optimal timing of antifungal therapy. We conducted a trial to analyze the efficacy and safety of voriconazole in the prevention of lung infiltrates during induction chemotherapy for acute myelogenous leukaemia (AML). Methods This was a prospective, randomised, double-blind, placebo-controlled phase III trial in AML patients undergoing remission induction chemotherapy. Oral voriconazole 200mg twice daily or placebo was administered until detection of a lung…

Microbiology (medical)AdultMalePosaconazolemedicine.medical_specialtyAntifungal AgentsAdolescentAdministration OralNeutropeniaPlacebolaw.inventionPlacebosRandomized controlled trialDouble-Blind MethodlawInternal medicinemedicineHumansProspective StudiesAgedVoriconazoleLeukopeniaLung Diseases Fungalbusiness.industryIncidenceInduction chemotherapyLength of StayMiddle AgedTriazolesmedicine.diseaseSurgeryClinical trialLeukemia Myeloid AcuteInfectious DiseasesPyrimidinesMycosesFemaleVoriconazolemedicine.symptombusinessmedicine.drugThe Journal of infection
researchProduct

Differentiation of Candida parapsilosis, C. orthopsilosis, and C. metapsilosis by specific PCR amplification of the RPS0 intron

2011

Although Candida parapsilosis is the most prevalent among the 3 species of the *psilosis group, studies applying DNA-based diagnostic techniques with isolates previously identified as C. parapsilosis have revealed that both C. orthopsilosis and C. metapsilosis account for 0-10% of all these isolates, depending on the geographical area. Differences in the degrees of antifungal susceptibility and virulence have been found, so a more precise identification is required. In a first approach, we reidentified 38 randomly chosen clinical isolates, previously identified as C. parapsilosis, using the RPO2 (CA2) RAPD marker. Among them, we reclassified 4 as C. metapsilosis and 5 as C. orthopsilosis. W…

Microbiology (medical)Antifungal AgentsSequence analysisGenes FungalMolecular Sequence DataVirulenceMicrobial Sensitivity TestsBiologyCandida parapsilosisPolymerase Chain ReactionMicrobiologyMicrobiologylaw.inventionSpecies SpecificityDrug Resistance FungallawCloning MolecularDNA FungalMycological Typing TechniquesGenePolymerase chain reactionCandidaDNA PrimersGeneticsBase SequenceIntronFungal geneticsSequence Analysis DNAGeneral Medicinebiology.organism_classificationIntronsRandom Amplified Polymorphic DNA TechniqueRAPDInfectious Diseases
researchProduct

Genetic structure of Triatoma venosa (Hemiptera: Reduviidae): molecular and morphometric evidence.

2006

Triatoma venosa presents a restricted geographical distribution in America and is considered as a secondary vector of Chagas disease in Colombia and Ecuador. A total of 120 adult insects were collected in domestic and peridomestic habitats in an endemic area of the department of Boyaca, Colombia, in order to determine their genetic structure through morphometric and molecular techniques. The head and wings of each specimen were used for the analyses of size, shape, and sexual dimorphism. A significant sexual dimorphism was found, although no differences in size among the studied groups were detected. Differences were found in the analyzed structures except for male heads. DNA was extracted …

Microbiology (medical)Chagas diseaseMalelcsh:Arctic medicine. Tropical medicinelcsh:RC955-962Triatoma venosalcsh:QR1-502Zoologyvector controllcsh:Microbiologyrandom amplified polymorphic DNADNA Ribosomal SpacermedicineAnimalsTriatomageometric morphometryinternal transcriber space-2Sex Characteristicsbiologybiology.organism_classificationmedicine.diseaseHemipteraRAPDInsect VectorsRandom Amplified Polymorphic DNA TechniqueSexual dimorphismGenetics PopulationReduviidaeVector (epidemiology)Genetic structureFemaleTriatoma venosaMemorias do Instituto Oswaldo Cruz
researchProduct

Immunogenicity of routinely used childhood vaccines when coadministered with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D…

2009

Background The choice of non-typeable Haemophilus influenzae Protein D as main carrier protein in the candidate 10-valent pneumococcal conjugate vaccine (PHiD-CV, GlaxoSmithKline Biologicals), was driven in part to avoid carrier-mediated suppression and possible bystander interference with coadministered vaccines. Immunogenicity data from 3 primary and 2 booster vaccination studies were assessed for possible impacts of PHiD-CV coadministration on immune responses to routinely administered childhood vaccines, in comparison to 7-valent pneumococcal conjugate vaccine (7vCRM) coadministration. Methods Randomized, controlled studies in which PHiD-CV or 7vCRM vaccines were coadministered with DTP…

Microbiology (medical)Heptavalent Pneumococcal Conjugate VaccineLipoproteinsImmunization SecondaryMeningococcal VaccinesBooster dosemedicine.disease_causeAntibodies Viralcomplex mixturesPneumococcal conjugate vaccineHaemophilus influenzaePneumococcal VaccinesBacterial ProteinsConjugate vaccineHeptavalent Pneumococcal Conjugate VaccineMedicineHumansHepatitis B VaccinesVaccines CombinedDiphtheria-Tetanus-Pertussis VaccineImmunization ScheduleHaemophilus VaccinesRandomized Controlled Trials as TopicVaccines Conjugatebusiness.industryImmunization ProgramsDiphtheriaImmunogenicityVaccinationInfantImmunoglobulin Dmedicine.diseaseVirologyAntibodies BacterialVaccinationPoliovirus VaccinesInfectious DiseasesTreatment OutcomePediatrics Perinatology and Child HealthImmunologybusinessCarrier Proteinsmedicine.drugThe Pediatric infectious disease journal
researchProduct

Chronic hepatitis B: who to treat and which choice of treatment?

2009

The goal of antiviral therapy in patients with chronic hepatitis B is to prevent, through persistent suppression of HBV replication, cirrhosis and hepatocellular carcinoma. Currently, seven drugs are available: IFN-alpha, pegylated interferon, lamivudine, adefovir dipivoxil, entecavir, telbivudine and tenofovir. The choice of the drugs should always take into consideration the clinical features of patients, the antiviral efficacy of each drug, the risk of developing resistance, the long-term safety profile, the method of administration and the cost of therapy. Ideal candidates for treatment are hepatitis B e antigen-positive patients with a prolonged phase of immune clearance and hepatitis …

Microbiology (medical)Liver Cirrhosismedicine.medical_specialtyHepatitis B virusCarcinoma Hepatocellularmedicine.disease_causeVirus ReplicationMicrobiologyGastroenterologyAntiviral AgentsDrug Administration ScheduleHepatitis B ChronicPegylated interferonVirologyTelbivudineInternal medicineDrug Resistance ViralmedicineAdefovirHumansRandomized Controlled Trials as TopicHepatitis B virusbusiness.industryNucleotidesLamivudineNucleosidesEntecavirHepatitis Bmedicine.diseaseVirologyInfectious DiseasesPractice Guidelines as TopicHepatitia BbusinessViral hepatitisantiviral Therapymedicine.drugExpert review of anti-infective therapy
researchProduct

Efficacy and safety of clarithromycin as treatment for Mediterranean spotted fever in children: a randomized controlled trial

2001

Fifty-one children with Mediterranean spotted fever (MSF) were randomized to receive either clarithromycin, 15 mg/kg/ day orally in 2 divided doses, or chloramphenicol, 50 mg/ kg/day orally in 4 divided doses, for 7 days. Mean time to defervescence was 36.7 h in the clarithromycin group and 47.1 h in the chloramphenicol group (P = .047). Clarithromycin could be an acceptable therapeutic alternative to chloramphenicol and to tetracyclines for children aged <8 years with MSF.

Microbiology (medical)Malemedicine.medical_specialtyBoutonneuse FeverGastroenterologylaw.inventionRandomized controlled trialOral administrationlawClarithromycinInternal medicineClarithromycinmedicineHumansChildAntibacterial agentclarithromycin Mediterranean spotted feverbusiness.industryChloramphenicolmedicine.diseaseSpotted feverSurgeryAnti-Bacterial AgentsBoutonneuse feverInfectious DiseasesRickettsiosisChloramphenicolChild PreschoolFemalebusinessmedicine.drug
researchProduct

Comparative clinical trial of ceftazidime and imipenem/cilastatin in patients with severe nosocomial pneumonias and septicaemias.

1990

The efficacy and safety of ceftazidime and imipenem in patients with severe infections was compared in a randomized multi-centre trial. Patients on assisted respiration with clinical signs of pneumonia or septicaemia who had been in hospital for at least 3 days were studied. Twenty-one patients were treated with ceftazidime, 24 with imipenem. The mean duration of treatment was 9 days in both groups. At the end of the trial 17 patients (81%) of the ceftazidime group and 16 patients (67%) in the imipenem group were clinically cured or showed marked improvement. The bacteriological results showed an eradication of the causative pathogens in 17 of 21 cases in the ceftazidime group and 13 of 19 …

Microbiology (medical)Malemedicine.medical_specialtyImipenemCeftazidimeHospital-acquired pneumoniaCeftazidimeInternal medicineSepsismedicineHumansMulticenter Studies as TopicIn patientRandomized Controlled Trials as TopicCross Infectionbusiness.industryImipenem/cilastatinGermany WestGeneral MedicinePneumoniaMiddle Agedbacterial infections and mycosesmedicine.diseaseRespiration ArtificialSurgeryClinical trialPneumoniaDrug CombinationsImipenemInfectious DiseasesCilastatinFemalebusinessmedicine.drugThe Journal of hospital infection
researchProduct

SCAR-based real time PCR to identify a biocontrol strain (T1) of Trichoderma atroviride and study its population dynamics in soils.

2006

Strains of Trichoderma spp. are known for their antagonistic properties against plant pathogens, some are already on the market, others are under development. In order to launch a strain on the market its perfect identification at the species and strain levels is needed. The aim of this study is to (i) design a SCAR marker for specific identification of strain T1 of Trichoderma atroviride and (ii) monitor population dynamics of this strain in soil by real time PCR. A primer pair targeting a 141-bp fragment enabled specific detection of this strain without cross detection of autochthonous populations of Trichoderma in several field soils. In two soils, population dynamics assessed by real ti…

Microbiology (medical)PopulationBiologycomplex mixturesMicrobiologyPolymerase Chain Reactionlaw.inventionlawREAL-TIME PCReducationDNA FungalMolecular BiologyPolymerase chain reactionSoil MicrobiologyTrichodermaeducation.field_of_studyStrain (chemistry)business.industryFungal geneticsfood and beveragesFungi imperfectiSequence Analysis DNAbiology.organism_classificationDNA FingerprintingSOILSBiotechnologyRandom Amplified Polymorphic DNA TechniquePOPULATION DYNAMICSSCAR[SDV.MP]Life Sciences [q-bio]/Microbiology and ParasitologyTrichodermabusinessSoil microbiologySpecific identificationJournal of microbiological methods
researchProduct